Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	179.95	128.45	69.33	75.05	93.12	203.43
Short-Term Investments	192.11	180.22	384.28	179.82	368.21	136.25
Cash & Short-Term Investments	372.07	308.67	453.61	254.87	461.33	339.68
Cash Growth	-28.80%	-31.95%	77.98%	-44.75%	35.81%	-19.61%
Receivables	211.66	187.8	142.08	144.16	165.5	148.93
Inventory	83.92	82.39	54.29	77.41	91.54	85.96
Prepaid Expenses	55.85	65.33	36.09	16.68	15.78	27.02
Total Current Assets	723.5	644.18	686.07	493.11	734.15	601.59
Property, Plant & Equipment	35.62	37.24	36.02	42.52	44.08	52.32
Long-Term Investments	-	-	-	16.62	93.9	119.17
Goodwill	119.43	124.88	117.02	117.02	117.02	117.52
Other Intangible Assets	469.46	569.46	521.91	599.89	702.46	784.69
Long-Term Deferred Tax Assets	49.06	38.35	-	-	-	-
Other Long-Term Assets	31.04	38.53	7.05	8.51	10.9	13.87
Total Assets	1,428	1,453	1,368	1,278	1,703	1,689

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5.59	2.68	4.59	1.96	10.54	9.33
Accrued Expenses	254.23	217.81	180.21	166.26	185.67	199.47
Current Portion of Long-Term Debt	-	-	-	-	407.97	7.24
Current Portion of Leases	10.74	10.61	6.89	8.33	6.79	6.48
Other Current Liabilities	76.81	107.07	100.72	113.64	76.99	92.86
Total Current Liabilities	347.38	338.17	292.4	290.2	687.96	315.38
Long-Term Debt	-	-	-	-	-	385.23
Long-Term Leases	29.43	30.37	27.38	33.2	36	41.3
Long-Term Deferred Tax Liabilities	-	-	4.96	24.96	49.81	85.36
Other Long-Term Liabilities	20.08	22.4	7.6	7.8	42.54	46.04
Total Liabilities	396.88	390.93	332.34	356.16	816.3	873.3

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.06	0.06	0.06	0.06	0.05	0.05
Additional Paid-In Capital	574.09	543.83	479.44	439.49	408.12	434.34
Retained Earnings	457.21	517.88	556.43	482.56	481.25	379.92
Comprehensive Income & Other	-0.14	-0.04	-0.19	-0.59	-3.21	1.54
Shareholders' Equity	1,031	1,062	1,036	921.52	886.2	815.85
Total Liabilities & Equity	1,428	1,453	1,368	1,278	1,703	1,689

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	40.17	40.98	34.27	41.53	450.76	440.25
Net Cash (Debt)	331.9	267.69	419.34	229.96	104.47	18.6
Net Cash Growth	-32.38%	-36.16%	82.35%	120.12%	461.74%	-94.47%
Net Cash Per Share	5.78	4.74	7.49	4.14	1.69	0.34
Filing Date Shares Outstanding	58.13	57.58	55.81	54.73	54.38	53.39
Total Common Shares Outstanding	58.16	57.46	55.74	54.72	54.25	53.26
Working Capital	376.12	306.01	393.67	202.92	46.19	286.21
Book Value Per Share	17.73	18.48	18.58	16.84	16.33	15.32
Tangible Book Value	442.34	367.38	396.8	204.61	66.72	-86.36
Tangible Book Value Per Share	7.60	6.39	7.12	3.74	1.23	-1.62
Machinery	15.36	14.87	14.48	14.03	13.11	14.23
Construction In Progress	-	-	-	-	0.21	0.03
Leasehold Improvements	13.05	13.05	14.02	14.02	14.02	14.37

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error